We approached the financing of the biotech firms (BF) according to two mainstreams of research, the financing constraints (FC) and the capital structures (CS). Our objective was to look for the existence of the FC and a particular CS for high tech firms from an international point of view. To do so, we placed the countries of our sample into models of capitalism. On the one hand, we had the BF of the “neo- or ultra-liberal” countries (LC), and on the other hand, the BF of the “intermediate” countries (IC). Comparison of the models then allowed us to observe “systemic” differences in terms of our objective. Individual factors (the characteristics of the BF) and cyclical factors (taken into account by the stock market crash of spring 2000) were integrated as other determinants of BF's financing conditions. From this triple approach (structural, cyclical and individual) it emerges (according to panel data) that some differences can be observed at the aggregated level between LC and IC, and within LC (between USA alone and USA excluded) which are in the FC or CS. Nevertheless, the data indicate that the public stock issues are very important everywhere in our sample in terms of FC and CS but that the BF's cost of capital is not significant.